Challenging interpretation of germline TP53 variants based on the experience of a national comprehensive cancer centre

[1]  William J. R. Longabaugh,et al.  The TP53 Database: transition from the International Agency for Research on Cancer to the US National Cancer Institute , 2022, Cell Death & Differentiation.

[2]  A. Patócs,et al.  Case Report: A Novel Pathomechanism in PEComa by the Loss of Heterozygosity of TP53 , 2022, Frontiers in Oncology.

[3]  A. Patócs,et al.  Reclassification of Five BRCA1/2 Variants with Unknown Significance Using Complex Functional Study , 2022, Cancer research and treatment.

[4]  S. Savage,et al.  Cancer incidence, patterns, and genotype-phenotype associations in individuals with pathogenic or likely pathogenic germline TP53 variants: an observational cohort study. , 2021, The Lancet. Oncology.

[5]  P. Hainaut,et al.  Analysis of the Li-Fraumeni Spectrum Based on an International Germline TP53 Variant Data Set , 2021, JAMA oncology.

[6]  D. Evans,et al.  TP53, a gene for colorectal cancer predisposition in the absence of Li-Fraumeni-associated phenotypes , 2020, Gut.

[7]  A. Spurdle,et al.  Genotype-phenotype correlations among TP53 carriers: Literature review and analysis of probands undergoing multi-gene panel testing and single-gene testing. , 2020, Cancer genetics.

[8]  E. Schröck,et al.  Guidelines for the Li–Fraumeni and heritable TP53-related cancer syndromes , 2020, European Journal of Human Genetics.

[9]  A. Spurdle,et al.  Specifications of the ACMG/AMP variant interpretation guidelines for germline TP53 variants , 2020, medRxiv.

[10]  P. Ashton-Prolla,et al.  TP53 variants of uncertain significance: increasing challenges in variant interpretation and genetic counseling , 2019, Familial Cancer.

[11]  T. Soussi,et al.  High prevalence of cancer‐associated TP53 variants in the gnomAD database: A word of caution concerning the use of variant filtering , 2019, Human mutation.

[12]  P. Hainaut,et al.  Variable population prevalence estimates of germline TP53 variants: A gnomAD‐based analysis , 2018, Human mutation.

[13]  Marina T. DiStefano,et al.  Recommendations for interpreting the loss of function PVS1 ACMG/AMP variant criterion , 2018, Human mutation.

[14]  R. Gelman,et al.  Differences in TP53 Mutation Carrier Phenotypes Emerge From Panel-Based Testing , 2018, Journal of the National Cancer Institute.

[15]  Alexandros Kouris,et al.  VarSome: the human genomic variant search engine , 2018, bioRxiv.

[16]  Sarah E. Brnich,et al.  Navigating the nuances of clinical sequence variant interpretation in Mendelian disease , 2018, Genetics in Medicine.

[17]  Cristina Has,et al.  Faculty of 1000 evaluation for Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. , 2018 .

[18]  Keith Nykamp,et al.  Sources of discordance among germ-line variant classifications in ClinVar , 2017, Genetics in Medicine.

[19]  Soma Das,et al.  Clinical Laboratories Collaborate to Resolve Differences in Variant Interpretations Submitted to ClinVar , 2017, Genetics in Medicine.

[20]  Quan Li,et al.  InterVar: Clinical Interpretation of Genetic Variants by the 2015 ACMG-AMP Guidelines. , 2017, American journal of human genetics.

[21]  J. Olson,et al.  Variability in assigning pathogenicity to incidental findings: insights from LDLR sequence linked to the electronic health record in 1013 individuals , 2017, European Journal of Human Genetics.

[22]  Ricardo Villamarín-Salomón,et al.  ClinVar: public archive of interpretations of clinically relevant variants , 2015, Nucleic Acids Res..

[23]  Bale,et al.  Standards and Guidelines for the Interpretation of Sequence Variants: A Joint Consensus Recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology , 2015, Genetics in Medicine.

[24]  H. Meijers-Heijboer,et al.  TP53 germline mutation testing in 180 families suspected of Li–Fraumeni syndrome: mutation detection rate and relative frequency of cancers in different familial phenotypes , 2010, Journal of Medical Genetics.

[25]  Catherine Bonaïti-Pellié,et al.  2009 version of the Chompret criteria for Li Fraumeni syndrome. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  S. Sommer,et al.  Beyond Li Fraumeni Syndrome: clinical characteristics of families with p53 germline mutations. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  C. Bonaïti‐pellié,et al.  Molecular basis of the Li–Fraumeni syndrome: an update from the French LFS families , 2008, Journal of Medical Genetics.

[28]  R. Audisio,et al.  Bridging The Age Gap: observational cohort study of effects of chemotherapy and trastuzumab on recurrence, survival and quality of life in older women with early breast cancer , 2021, British Journal of Cancer.